Menu

ImmunityBio, Inc. IBRX

Full chart Compare
Set alert

Price alert · IBRX

All alert types
6.67 USD -0.08 (-1.11%)

At closeNov 11, 2026, 7:48 PM EST

6.63 -0.04 -0.60%

After hours · Nov 11, 7:48 PM ET

6.51 Day range 6.85
1.95 52-week range 12.43
YTD
+236.87%
1 year
+211.68%

Discussion (3500)

Sign in to join the discussion

frank fager IBRX 3 months ago #661

Well no premarket news

Maybe Dr PSS is planing to group all news and release it all together with sales and earnings. Give guidance based on the news

frank fager IBRX 3 months ago #662

Ok chart says sell buy back later shorts are in trouble or not what does your chart say

LMAO at you bunch of 🤡s

frank fager IBRX 3 months ago #663

I have 640,000 shares would like to sell some at $15 plus maybe about 140,000 plan for the other 500,000 hold for $50 $75 $100 $150 $200 $250 $300 and beyond

frank fager IBRX 3 months ago #664

Indian idle you posted the exact same thing before and I let the stupidity of it slide.
Please don't keep reposting your idiotic thoughts over and over and waste our time.

frank fager IBRX 3 months ago #665

Indian idle

Keytruda cost 12k-25k per dose and requires multiple treatments. Keytruda sales are over 30 billion a year so your entire post is stupid. Nearly all immunotherapies and chemo and radiation costs 100s of thousands and doesn't even work. Do some real research don't just fabricate crap and post.

frank fager IBRX 3 months ago #666

Rob Bauer

what does your post have to do with IBRX???

Go post that stuff on censorbook please.

frank fager IBRX 3 months ago #667

Daredevil go fuck yourself with broom handle full of splinters

frank fager IBRX 3 months ago #668

IBRX is getting to start the run for $15 buy 2-1-2027 maybe much higher

frank fager IBRX 3 months ago #669

👿 pleas go 👉👿 yourself 🖕off you evil POS disgusting human or bot

frank fager IBRX 3 months ago #670

All we need is fair MSM coverage after papillary approval and an interview with Dr PSS on CNBC or FoxB or both and it's $50 plus when the world knows what we know.